The rapid increase in the incidence of multidrug-resistant infections today has led to enormous interest in antimicrobial peptides (AMPs) as suitable compounds for developing unusual antibiotics. In this study, clavanin A, an antimicrobial peptide previously isolated from the marine tunicate Styela clava, was selected as a purposeful molecule that could be used in controlling infection and further synthesized. Clavanin A was in vitro evaluated against Staphylococcus aureus and Escherichia coli as well as toward L929 mouse fibroblasts and skin primary cells (SPCs). Moreover, this peptide was challenged here in an in vivo wound and sepsis model, and the immune response was also analyzed. Despite displaying clear in vitro antimicrobial activity toward Gram-positive and -negative bacteria, clavanin A showed no cytotoxic activities against mammalian cells, and in acute toxicity tests, no adverse reaction was observed at any of the concentrations. Moreover, clavanin A significantly reduced the S. aureus CFU in an experimental wound model. This peptide also reduced the mortality of mice infected with E. coli and S. aureus by 80% compared with that of control animals (treated with phosphate-buffered saline [PBS]): these data suggest that clavanin A prevents the start of sepsis and thereby reduces mortality. These data suggest that clavanin A is an AMP that could improve the development of novel peptide-based strategies for the treatment of wound and sepsis infections.
T hroughout life, the human body continuously interacts with different types of microorganisms, including commensal bacteria that colonize skin and mucous membranes (1) . In most cases, invading pathogens can be effectively eradicated by our immune system. Nowadays, infectious diseases remain a major health problem, accounting for around 18% of deaths worldwide (1) . The skin has the largest surface area of all the body organs and is the most exposed of them. Although the skin provides effective protection from the external environment, skin infections can occur by bacteria, fungi, or viruses. These infections are often the result of a breach of skin integrity, accompanied by the entry of pathogens into the dermis (2) .
Skin infections are quite common, but when treated quickly are not usually dangerous. However, in cases where the patient remains with an untreated infection, it can evolve to a more serious condition, which can lead to sepsis and death (3, 4) . The most frequent bacterial sepsis-associated species are Staphylococcus aureus (30%, including 14% methicillin resistant), Pseudomonas spp. (14%), and Escherichia coli (13%) (5) . Sepsis is a complex and dynamic disease characterized by an exacerbated and systemic immune response to invading pathogens or their related toxins (6, 7) . This immune response includes pathogen recognition, which triggers the release of inflammatory mediators, such as peptides and proteins, as well as systemic activation of the complement and coagulation cascade (6) . Despite improvements in health care procedures, the incidence of sepsis has increased in recent years, increasing mortality and the period of hospitalization (3, 6) .
Currently, several alternative approaches are used for the treatment of local and systemic bacterial infections, producing effec-tive results in clinical trials (8, 9) . Therefore, the investigation of new and unusual therapies is vitally important. In this context, antimicrobial peptides (AMPs) appear to be excellent candidates. AMPs are major short cationic and amphipathic molecules (Ͻ60 amino acid residues) with heterogeneous and multiple action modes that may directly lead to bacterial death, besides having immunomodulatory activity (10, 11) . The search for novel antibiotics has become more intense in recent decades, in response to increasingly frequent reports of multiresistant pathogens or the side effects caused by antibiotics on the market today (10) .
Clavanin A consists of an AMP isolated from the hemocytes of the marine tunicate Styela clava (12) . In addition to cationic amphipathic characteristics, this peptide also presents a sequence rich in histidine, phenylalanine, and glycine residues (13) . Clava-nin A is broadly effective against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and Gram-negative bacteria and fungi (12, 14) . These peptides are also active in high-salt concentrations and in acidic pH. Nevertheless little is known about the proteolytic and thermal stability of clavanin forms (12, 14) . Due to these special characteristics, clavanin A was investigated in this study with regard to its biological properties, such as its antibacterial activity (in vitro and in vivo) and toxicity.
MATERIALS AND METHODS
Peptide synthesis. All peptides used here (clavanin A and the cathelicidin LL-37) were synthesized by Shanghai Hanhong Chemical (China) using the solid phase with the N-9-fluorenylmethyloxycarbonyl (Fmoc) strategy and purified by high-performance liquid chromatography (HPLC) (12, 15) . The purity of the peptide used in biologic assays was higher than 95%. Moreover, the primary structure (data not shown) and molecular mass (see Fig. S1 in the supplemental material) were confirmed by matrixassisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) analysis.
Bactericidal microdilution assays. Clavanin A MICs against Escherichia coli ATCC 8739 and Staphylococcus aureus ATCC 29213 were determined using a standardized dilution method according to North Carolina Special Libraries Association (NCSLA) guidelines (16) . A single colony of E. coli or S. aureus was inoculated in Mueller-Hinton (MH) broth (Himedia, India) and incubated for 12 h at 37°C. Overnight-cultured E. coli or S. aureus cells were transferred to MH medium and cultured to the exponential phase (optical density at 600 nm [OD 600 ] of ϳ0.6). The culture was centrifuged and resuspended in sterile phosphatebuffered saline (PBS) and adjusted to a final amount of 1 ϫ 10 5 CFU ml Ϫ1 by using the equation CFU ml Ϫ1 ϭ OD 600 ϫ 2.5 ϫ 10 8 (17) . For MIC determination, peptides were used at variable concentrations (1 to 200 M) from a stock solution. Ten microliters of each concentration of peptide solution was added to each corresponding well of a 96-well plate (Becton and Dickinson), and 90 l of bacteria (1 ϫ 10 5 ) in MH medium was added. The polypropylene plates (TPP, Switzerland) were incubated at 37°C for 24 h. The MIC was determined as the lowest tested concentration that leads to complete inhibition (100%) in comparison to the negative-control group (18) .
Animals. C57BL/6 mice weighing 18 to 22 g were used in this study. Animals were provided by the Central Bioterium of the University of São Paulo Campus in Ribeirão Preto, Brazil. All animals were housed in individual cages under a constant temperature (22°C) and humidity with a 12-h light/dark cycle and had access to food and water ad libitum throughout the study. The mice were euthanized by CO 2 or ether inhalation at the end of the experiments. All procedures, care, and handling of the animals were approved by the Ethics Committee of the Catholic University of Brasilia (no. 005/13. Isolation and culture of cells. Newborn C57BL/6 mice were used to isolate skin primary cells (SPCs). First, mice were euthanized by decapitation, and the entire trunk skin was removed. Biopsy specimens (ϳ5 mm) were incubated overnight with 0.1% trypsin (Sigma)-0.02% EDTA in PBS, followed by mechanical separation of epidermis from dermis. The treatment solution was filtered through a 100-m-pore cell strainer, centrifuged, and resuspended in supplemented Dulbecco's modified Eagle's medium (DMEM) (Gibco-Invitrogen) (4 mM L-glutamine, 10% fetal bovine serum [FBS; Gibco-Invitrogen], 2 mM nonessential amino acids [Gibco-Invitrogen], 50 mg ml Ϫ1 gentamicin, and 100 U ml Ϫ1 penicillin-streptomycin [GIBCO-Invitrogen]), seeded into tissue culture flasks (TPP, Switzerland), and incubated at 37°C in 5% CO 2 (19) . L929 mouse fibroblasts were also cultured in supplemented DMEM, poured into a tissue culture flask (TPP, Switzerland), and incubated at 37°C in 5% CO 2 (18, 20) .
Cell cytotoxicity assay. L929 mice fibroblasts (Rio de Janeiro Cell Bank) and SPCs were seeded in 96-well microtiter plates at a concentration of 1.0 ϫ 10 5 cells per well in DMEM supplemented with different concentrations of the tested peptides (1 to 600 M). After 48 h of incu-bation, a 3-(4,5-dimethyl-2-thiazolyl-2,5-diphenyl-2H-tetrazolium bromide (MTT) protocol was performed. Briefly, 60% of the medium was removed, 10 l (5 mg ml Ϫ1 ) of MTT (Sigma) solution was added to each well, and the plate was incubated for 4 h in 5% CO 2 at 37°C. The blue formazan product generated was dissolved by the addition of 100 l of 100% dimethyl sulfoxide (DMSO) (Mallinckrodt, Germany) per well. Plates were then gently swirled for 5 min at room temperature to dissolve the precipitate. The absorbance was monitored at 575 nm using a microplate spectrophotometer (Bio-Tek). Cytotoxicity was determined as a percentage of the maximum value after subtracting the background. The results were expressed as the percentage of each sample compared to that of the negative control (PBS buffer, pH 7.4) and the cell culture was incubated in a lysis buffer (10 mM Tris [pH 7.4], 1 mM EDTA, 0.1% Triton X-100) (16) .
Acute toxicity. The acute toxicity experiment was performed based on the work of Navon-Venezia and coworkers (21) . The experiment was examined by intraperitoneal (i.p.) injection of the tested clavanin A into groups of 10 C57BL/6 mice. Each mouse was injected with a 0.5-ml solution of freshly prepared clavanin A in PBS. The doses of peptide administered per mouse were 0, 5, 10, 20, 30, 40, and 50 mg kg Ϫ1 of body weight. Animals were directly inspected for adverse effects for 4 h, and mortality was monitored for 7 days thereafter. Differences between groups were analyzed using the Fisher exact test (differences were considered to be statistically significant when the P value was Ͻ0.05).
Murine surgical wound infection model. The murine surgical wound infection model was performed as previously described by McRipley and Whitney (22) , with minor modifications. Mice (n ϭ 6 per group) were anesthetized, their dorsal surface was shaved, and the surgical area was disinfected with 70% ethanol. An incision was performed in the dorsal surface with 6-mm punch biopsy needles (Stiefel Laboratories, United Kingdom), and then 10 l of S. aureus ATCC 29213 suspension (2 ϫ 10 9 ml Ϫ1 ; previously cultured as described in the section on bactericidal microdilution assays) was introduced into the incision, and the skin was closed with one silk suture (23) . The wounds were treated every 24 h with 20 l of clavanin A solution (solubilized in PBS buffer [Gibco]) containing 1, 5, or 10 mg kg Ϫ1 , as well as with a solution of LL-37 (solubilized in PBS buffer [Gibco] ) and gentamicin injection (as gentamicin sulfate USP, 100 mg ml Ϫ1 [Merck, Germany]) (10 mg kg Ϫ1 ) as positive controls and PBS (Gibco) as the negative control; for this, animals were mobilized manually, and treatments were applied with the aid of an automatic pipette. Mice were euthanized at 7 days postsurgery, the wounded muscle tissue was excised and weighed, and half of it was homogenized in 1 ml of PBS. Serial dilutions of the homogenates were plated in triplicate on mannitol salt agar (Himedia, India), and the results were expressed as CFU g Ϫ1 of tissue (17, 24) . The other half of the wounded tissue was stored for histological analysis as described previously by Lima and coworkers (25) . Murine lethal infection model. Mice received an intraperitoneal injection of 100 l E. coli ATCC 8739 or S. aureus ATCC 29213 containing 2 ϫ 10 9 CFU ml Ϫ1 . One hour after the S. aureus injection, mice (n ϭ 6) were treated intraperitoneally with different concentrations of clavanin A (1, 5, or 10 mg kg Ϫ1 ), LL-37, and gentamicin (10 mg kg Ϫ1 ) or PBS for 7 days (26) .
Cytokine assays. Proinflammatory cytokines gamma interferon (IFN-␥), interleukin-6 (IL-6), IL-12p70, and tumor necrosis factor alpha (TNF-␣) were measured in the plasma of mice subjected to the lethal E. coli and S. aureus infection model, 24 h after infection, using an enzymelinked immunosorbent assay (ELISA) kit (Peprotech) according to the manufacturer's instructions (18) .
Statistical analysis. Data are presented as means Ϯ standard deviations (SD) of values from all samples. Statistical significance of differences in fatality rates between different groups was analyzed by Kaplan-Meier test. The other data were submitted to one-way analysis of variance (ANOVA) followed by Tukey's test. P values of Ͻ0.05 were considered statistically significant. GraphPad Prism software v5.0 (GraphPad Software) was used for all statistical analyses (18) .
RESULTS
In vitro antibacterial activity of clavanin A. The effects of clavanin A on E. coli ATCC 8739 and S. aureus ATCC 29213 were studied by the microdilution method. As shown in Table 1 , the MICs demonstrate that clavanin A was more effective against E. coli (MIC of 24 M) than S. aureus (MIC of 45 M). Clavanin A was as potent as gentamicin against S. aureus. However, the MIC of LL-37 was approximately three times lower (12.5 M) than that of clavanin A. LL-37 and gentamicin (MICs of 1.5 and 0.7 M, respectively) were highly effective against E. coli, presenting greater overall potency than clavanin A in in vitro assays.
Effects of clavanin A in cell viability/metabolism. Clavanin A cytotoxic effects on L929 mouse fibroblasts and mouse skin primary cells (SPCs) were determined. Cell viability (cell oxidative metabolism) was measured by MTT assay after 48 h of treatment with different clavanin A concentrations.
Clavanin A cytotoxic effects on L929 mouse fibroblasts and mouse skin primary cells (SPCs) were determined. Cell viability (cell oxidative metabolism) was measured by MTT assay after 48 h of treatment with different clavanin A concentrations. Differences between groups were analyzed using the Fisher exact test (with differences considered statistically significant when the P value was Ͻ0.05). LL-37 was used as a control. Clavanin A showed low cytotoxicity (viability over 60%) for L929 cells and SPCs, even when the cells were treated with high concentrations of clavanin A (600 M [P Ͻ 0.001]) ( Fig. 1a and b) . In contrast, LL-37 treatments reduced cell viability to approximately 10% of that of both cell types at higher concentrations (600 M [P Ͻ 0.001]). These results demonstrate that clavanin A did not show any significant cytotoxic effect on cultured cells, and peptide LL-37 did not ex-hibit cytotoxicity at the physiologically effective antibacterial concentrations.
Effects of clavanin A on S. aureus-infected wounds in mice. After confirmation of the in vitro antibacterial effects with the absence of cytotoxic activities of clavanin A on L929 mouse fibroblasts and primary mouse skin cells (SPCs), further in vivo experiments were performed. In order to evaluate the therapeutic potential of clavanin A, a model of surgical wound infection with S. aureus was used here. The animals were daily treated with solution containing 1, 5, or 10 mg kg Ϫ1 clavanin. Furthermore, LL-37 and gentamicin were used at a standard concentration of 10 mg kg Ϫ1 . All treatments were performed during a 7-day period.
Mice treated with PBS ( Fig. 2A) showed a healing process of the infection site damaged due to the presence of the microorganism, including little epithelialization, focal inflammation with intense polymorphonuclear and mononuclear cell infiltration, loose irregular connective tissue, and initial neovascularization (Fig. 2F ). Gentamicin-treated animals (Fig. 2B) showed a complete absence of bacteria and a stratified and well-developed epithelium with little keratinization. Moreover, gentamicin also caused diffuse inflammation with a clear predominance of polymorphonuclear cells and some fibroblasts, connective tissue with a well-developed collagen network, and clear vascularization, indicating early healing ( Fig. 2G ). Animals treated with 5 mg kg Ϫ1 clavanin A showed a lack of microorganisms, besides stratified and very-well-developed keratinized epithelial (Fig. 2C ) connective tissue with a dense network of collagen, predominantly (Fig. 2H ). Data obtained with clavanin at a lower concentration were very similar to those from gentamicin-treated animals. The animal group that received 10 mg kg Ϫ1 clavanin also showed a well-developed keratinized epithelium (Fig. 2D ) and scar contraction, indicating tissue recovery (Fig. 2I ). The animals that received 10-mg kg Ϫ1 LL-37 treatments were clear of bacterial infection, as observed with the uninfected animal group treated only with PBS ( Fig. 2E ). Furthermore, diffuse inflammation with predominantly polymorphonuclear cell infiltrate, intense neovascularization, and loose irregular connective tissue (Fig. 2J) were also observed.
CFU of S. aureus recovered from wounds. After 7 days of daily administration of clavanin A treatment, animals were euthanized, and the wound tissue was removed, macerated, plated, and seeded on mannitol salt agar (a selective medium for S. aureus) for eval- a Antibacterial activity was determined in three independent microtiter assays with a discrepancy of not more than 1 dilution.
FIG 1
Effects of clavanin A on cell viability/metabolic activity. The effects of clavanin A and LL-37 on viability/metabolic activity were determined using an MTT assay with L929 mouse fibroblasts (a) and mouse skin primary cells (SPCs) (b) at the indicated concentrations. Cells were incubated with peptides for 24 h. The standard deviation (SD) was calculated from three independent experiments, and results are shown as means Ϯ SD for statistical significance of clavanin A versus LL-37. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.005. uation of the treatment's efficacy. Clavanin A administration resulted in a significant dose-dependent decrease in wound bacterial count (P Ͻ 0.001) compared to PBS treatment. Mice treated with 10 mg kg Ϫ1 of clavanin A, gentamicin, and LL-37 presented statistically similar results, being able to practically eradicate all microorganisms present at the infection site ( Fig. 3) .
Effects of clavanin A on the murine lethal S. aureus and E. coli infection model.
The in vivo protective activity of clavanin A was also evaluated by using an invasive infection in the S. aureus model. All treatments were performed daily for 8 days. S. aureusinfected mice treated with clavanin A at a dose of 10 mg kg Ϫ1 showed a survival rate of 80% after 8 days of treatment (Fig. 4a ). Animals treated with 5 mg kg Ϫ1 of clavanin A showed a survival rate of 60%, the same percentage presented for animals treated with 10 mg kg Ϫ1 of the cathelicidin LL-37 (data not shown). Infected mice treated with 1 mg kg Ϫ1 of clavanin A showed a survival rate of 20%. Mice treated with 10 mg kg Ϫ1 of gentamicin showed 100% survival at the experiment endpoint. It is worth mentioning that clavanin A activity was dose dependent.
The efficacy of intraperitoneally administered clavanin A to counteract E. coli-induced infection in a mouse model was also tested. In this case, the lethality rate in the PBS control group was 100% (Fig. 4b ). All groups treated immediately after infection with clavanin A (1, 5, and 10 mg kg Ϫ1 ) showed a better outcome than control groups (PBS) (P Ͻ 0.05). The survival rates in mice were 40, 60, and 80% in the groups treated with clavanin A (1, 5, and 10 mg kg Ϫ1 , respectively) ( Fig. 4b ). Mice treated with gentamicin and LL-37 (10 mg kg Ϫ1 ) showed survival rates of 100% and 60%, respectively.
Analyses of cytokines 24 h after bacterial injection showed that mice infected by E. coli and treated with clavanin A, compared with the control group (PBS), had reductions in the proinflammatory cytokines IFN-␥ (55%) (Fig. 5A ), IL-6 (69%) (Fig. 5B ), IL-12p70 (69%) (Fig. 5C ), and TNF-␣ (68%) (Fig. 5D ). Similar data were obtained when S. aureus-infected mice were treated with clavanin A, showing reductions in proinflammatory IFN-␥ (53%) (Fig. 5A ), IL-6 (38%) (Fig. 5B ), IL-12p70 (39%) (Fig. 5C) , and TNF-␣ (52%) (Fig. 5D) .
DISCUSSION
In the present study, the in vitro antibacterial activities of clavanin A were determined against S. aureus and E. coli. The clavanin A MICs for E. coli and S. aureus shown here were higher than those described in the literature (Ͻ10 M) (13, 27, 28) . Apparently this is due to the fact that clavanin A presents better activity in environments containing elevated NaCl concentrations and a more acidic pH (14) . After confirmation of the in vitro antibacterial activity of clavanin A, its therapeutic potential was evaluated in two contrasting situations: first in an infected wound and second in a murine model of systemic infection. In our study, a surgical wound infected by S. aureus was used due to its high frequency (29) .
Here it was demonstrated that in addition to previous reports on in vitro antibacterial activities, (12) , clavanin A has potent activity in reducing the load of S. aureus in an in vivo wound model, showing higher efficiency than LL-37 ( Fig. 3) . Furthermore, clavanin A treatment showed lower cytotoxicity on in vitro assays for L929 cells and SPCs, being significantly less toxic than LL-37, and in acute toxicity tests, no adverse reactions were observed at any of the concentrations tested here (data not shown). These data corroborate the previous studies where clavanin A showed low cytotoxicity in human cell erythrocytes and HEp-2 as well as monkey cells of the Vero and MA104 lines (30) . Normally, cathelicidins are highly toxic to eukaryotic cells (29) . Although some cathelicidin peptides have been shown to be effective in some in vivo studies, there is a very small pharmacological window available, because the effective dose is very near the toxic dose (31, 32) . In addition to cathelicidins, other host defense peptides (HDPs), such as defensins (33) , magainins (34) , and temporins (35) , are also cytotoxic to mammalian cells. The data obtained show that despite a higher MIC, clavanin A deserves special attention due to its low cytotoxicity. Furthermore, clavanin A demonstrated a dose-dependent effect on reducing bacterial colonies in infected wounds and on the increase of survival in a systemic bacterial infection model.
In the infected murine surgical wound model, it was observed that clavanin A showed potent activity in reducing bacteria in the surgical site, reducing by ϳ10ϫ the bacterial load in wounds infected by S. aureus. Similar results were found by Malmsten and coworkers (36) , who proved the efficacy of a peptide derived from a sequence rich in arginine, leucine, and proline by using an ex vivo surgical wound model in pig skin infected with S. aureus and P. aeruginosa. Furthermore, topical administration of AMPs derived from halocidin HG1 exerted strong antimicrobial activity in a surgical wound model of infection with methicillin-resistant S. aureus in mice (37) . Cecropin peptide D2A21 also strongly inhibited P. aeruginosa growth in a wound model in rats (38) . Other unusual activities have also been reported. A trial using IDR-1018 showed accelerated healing despite a complete absence of antibacterial activity against S. aureus in in vivo wound models (17) . Another interesting peptide evaluated was pexiganan. This peptide was evaluated as a medication for topical use, presenting antimicrobial activity against Gram-positive and Gram-negative organisms that normally infect skin and soft tissues (39) . LL-37 treatment (control group) demonstrated a significant bacterial reduction in the surgical site, showing high cytotoxicity toward skin cells in vitro. However, LL-37-treated wounds showed decreased organization of the newly formed epithelium and reduced bacteria (2 ϫ 10 9 CFU ml Ϫ1 ), followed by i.p. injection of clavanin A (1, 5, and 10 mg kg Ϫ1 ), LL-37 (10 mg kg Ϫ1 ), and gentamicin (10 mg kg Ϫ1 ) or PBS only, after 1 h. The injections were repeated after 24 h for 8 days. Treatment with the peptide significantly increased survival (n ϭ 5 for controls and treated animal groups). reepithelialization compared to an equal dosage of clavanin A and gentamicin.
Given that sepsis may be caused by both Gram-negative and Gram-positive bacteria and can also start from a skin infection, clavanin A was also challenged in a systemic infection model against E. coli and S. aureus. Normally, Gram-negative bacterial sepsis is caused by the lipopolysaccharide (LPS) component of the outer membrane, while sepsis caused by Gram-positive bacteria is associated with the production of exotoxin production, as well as cell wall components, such as lipoteichoic acid (LTA) (40) . It is noteworthy that the antibacterial activity presented by clavanin A in the experimental model of systemic bacterial infection is peculiar, since the infected and treated animals showed a significant survival rate, which reached 80%. Comparing this finding with the literature, the same significance was observed, since animals receiving a lethal dose of E. coli cells and treated with 5 mg kg Ϫ1 of LL-37 showed only 28% survival (41) . The animals infected with E. coli and treated with clavanin A at standard concentration of 5 mg kg Ϫ1 showed 60% survival. In order to assess whether clavanin A and LL-37 act faster than gentamicin and if the reduction in cytokine response is merely a consequence of infection decreasing the health of these animals, the CFU count was evaluated just 24 h after infection. Groups treated with LL-37 and clavanin A 10 mg kg Ϫ1 showed a reduction in CFU with a significant difference from the control group (PBS), but there was no significant difference between these two groups and the group treated with gentamicin (see Fig. S2 in the supplemental material). These data suggest that modifications in the cytokine response probably occur due to reduction in bacterial growth.
In conclusion, clavanin A, a native AMP, has shown specific effects on the inhibition of E. coli and S. aureus proliferation and survival, and this peptide is as effective as LL-37, but significantly less toxic to the organism. These in vitro and in vivo antibacterial activities suggest that clavanin A will facilitate studies on the development of novel peptide-based strategies for the treatment of infected wounds and sepsis, opening new doors in the discovery of anti-infective drugs.
